Blogs
CATEGORIES [ ASCO, BREAST CANCER ]

From ASCO: Updates in HER2-positive breast cancers

BY DEBU TRIPATHY | JUNE 5, 2013

Debu Tripathy blog image
Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.

RELATED POSTS

COMMENTS

This is good news! I am currently on every three week tx with Taxotere-Herceptin-pertazunab, which was FDA approved last June. This combo was found to have a mean progression-free time of 6 mos, which feels like a lifetime for someone metastatic like myself. My oncologist told me that it would be rough, and it is-I'm not a big fan of Taxotere, but my PET back in Jan did show no progression, and some improvement. Being Her2+, I am so thankful for these new therapies!
- Posted by DebraD 6/14/13 10:52 AM

I credit A-C-T with Herceptin for saving my life with a dxg of Stg IIa IDC BC 7 yrs ago. I pray to continue to stay NED but if I do have an re-occurrence this is good news indeed. Will be waiting for large studies to see how it holds up
- Posted by Cindy Butler 8/14/13 11:09 PM

ADD A COMMENT

Your comment will appear once approved by CURE staff:
* Required fields